Dendreon (DNDN -1.3%) agrees to pay $40M to settle a class-action investor lawsuit that alleges...

|About: Dendreon Corporation (DNDN)|By:, SA News Editor

Dendreon (DNDN -1.3%) agrees to pay $40M to settle a class-action investor lawsuit that alleges that the company made "false or misleading statements," particularly about its Provenge cancer drug. Dendreon continues to deny that it made such statements, and says its insurers will pay $38M of the settlement. (PR)